secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001213900-22-071746
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Therapeutics reports Q3 2022 net loss of $5.6M and provides pipeline updates
--------------------------------------------------------------------------------

- Completed enrollment of pivotal bioequivalence study for RENAZORB; topline data expected by year-end.
- Entered partnership with Lee's Pharmaceutical for RENAZORB in China, receiving $1.0M upfront fee.
- Expects clearance for Phase 1 study of UNI-494 in UK by year-end.
- Net loss for Q3 2022 was $5.6M vs $5.2M in Q3 2021; cash and equivalents totaled $7.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390022071746/0001213900-22-071746-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390022071746/ea168550-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-071746

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer